Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (4)
  • Open Access

    ARTICLE

    Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of GNAL in glioma

    ZHEN LIU1,#, LIANGWANG YANG2,#, ZHENGXING XIE1, HUI YU3, TIANYI GU3, DAOMING SHI4, NING CAI1,*, SHENGHUA ZHUO2,*

    Oncology Research, Vol.32, No.5, pp. 965-981, 2024, DOI:10.32604/or.2024.045769 - 23 April 2024

    Abstract Clinical data indicates that glioma patients have poor treatment outcomes and clinical prognosis. The role of olfactory signaling pathway-related genes (OSPRGs) in glioma has not been fully elucidated. In this study, we aimed to investigate the role and relationship between OSPRGs and glioma. Univariate and multivariate Cox regression analyses were performed to assess the relationship between OSPRGs and the overall survival of glioma based on public cohorts, and the target gene (G Protein Subunit Alpha L, GNAL) was screened. The association of GNAL expression with clinicopathological characteristics, gene mutation landscape, tumor immune microenvironment (TIME), deoxyribonucleic acid… More >

  • Open Access

    REVIEW

    Underlying mechanisms and clinical potential of circRNAs in glioblastoma

    LEI ZHANG*, YUAN ZHANG, HUIJUAN GAO, XIN LI, PEIFENG LI*

    Oncology Research, Vol.31, No.4, pp. 449-462, 2023, DOI:10.32604/or.2023.029062 - 25 June 2023

    Abstract Glioblastoma (GBM) is the most malignant form of glioma and is difficult to diagnose, leading to high mortality rates. Circular RNAs (circRNAs) are noncoding RNAs with a covalently closed loop structure. CircRNAs are involved in various pathological processes and have been revealed to be important regulators of GBM pathogenesis. CircRNAs exert their biological effects by 4 different mechanisms: serving as sponges of microRNAs (miRNAs), serving as sponges of RNA binding proteins (RBPs), modulating parental gene transcription, and encoding functional proteins. Among the 4 mechanisms, sponging miRNAs is predominant. Their good stability, broad distribution and high More > Graphic Abstract

    Underlying mechanisms and clinical potential of circRNAs in glioblastoma

  • Open Access

    ARTICLE

    A pan-cancer analysis of the biological function and clinical value of BTLA in tumors

    XIANGLAI JIANG1,2,3,4,#, JIN HE2,#, YONGFENG WANG2,3,4,5,#, JIAHUI LIU5, XIANGYANG LI5, XIANGUI HE5, HUI CAI2,3,4,*

    BIOCELL, Vol.47, No.2, pp. 351-366, 2023, DOI:10.32604/biocell.2023.025157 - 18 November 2022

    Abstract B and T-lymphocyte attenuator (BTLA) plays an immunosuppressive role by inhibiting T- and B-cell functions. BTLA is associated with a variety of diseases, especially cancer immunity. However, the function of BTLA in various cancers and its clinical prognostic value have still not been comprehensively analyzed. This study aimed to identify the relationship between BTLA and cancer from the perspectives of differences in BTLA expression, its clinical value, immune infiltration, and the correlation with immune-related genes in various cancers. Data regarding mRNA expression, miRNA expression, lncRNA expression, and clinical data of patients of 33 existing cancers… More >

  • Open Access

    ARTICLE

    Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

    Guanling Chen1, Zhaoze Guo1, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye

    Oncology Research, Vol.25, No.9, pp. 1567-1578, 2017, DOI:10.3727/096504017X14897173032733

    Abstract Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC, eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS), and grades 3–5 adverse events. Capecitabine-based combination adjuvant chemotherapy demonstrated a 16% increase in BCSS (HR = 0.84, 95% CI = 0.71–0.98, p = 0.03) in the… More >

Displaying 1-10 on page 1 of 4. Per Page